

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

ANNOUNCEMENT ON THE PROPOSED TRANSFER OF 100% EQUITY INTEREST IN AN UPSTREAM SHAREHOLDER OF THE COMPANY'S CONTROLLING SHAREHOLDER

The board of directors (the "Board") and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the "Company") hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

The Board wishes to announce that, on 19 May 2026, the Company was informed by its controlling shareholder, Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司) ("TPH"), that SIIC Shanghai (Holdings) Co., Ltd. (上海上实(集团)有限公司) ("SIIC Holdings") and Shanghai SIIC Investment Development Co., Ltd. (上海上实投资发展有限公司) ("SIIC Investment Development") intend to dispose of their entire equity interest in Shanghai Liuliguang Medical Development Co., Ltd. (上海琉璃光医药发展有限公司) ("Liuliguang Medical"), representing 100% of the equity interest in Liuliguang Medical, through a public tender process on the Shanghai United Assets and Equity Exchange (上海联合产权交易所) ("SUAEE") (the "Proposed Transfer").

As at the date of this announcement:

- (a) TPH holds approximately 43.008% of the total issued share capital of the Company and is the direct controlling shareholder of the Company;
- (b) Jinhushen Biological Medical Science and Technology Co., Ltd. (津沪深生物医药科技有限公司) ("Jinhushen") and Tianjin Guoyu Enterprise Management Co., Ltd. (天津国宇企业管理有限公司) hold 67% and 33% of the equity interest in TPH, respectively;
- (c) Liuliguang Medical holds 35% of the equity interest in Jinhushen; and
- (d) SIIC Holdings and SIIC Investment Development hold 51% and 49% of the equity interest in Liuliguang Medical, respectively.

In accordance with the relevant laws and regulations of the People's Republic of China governing transactions of state-owned assets, including the *Measures for the Supervision and Administration of Transactions of State-Owned Assets of Enterprises* (企业国有资产交易监督管理办法), and the applicable transaction rules of the SUAEE, an information pre-disclosure in respect of the Proposed Transfer has been published on the SUAEE.

The information pre-disclosure period for the Proposed Transfer commences on 19 May 2026 and ends on 16 June 2026. Further details of the Proposed Transfer are set out in the relevant announcement published by the SUAEE on 19 May 2026, which may be accessed via the following link: <https://www.suaee.com/xmzx.html#/Detail?XMID=118995&PLZT=1>.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
19 May 2026